Flugen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.flugen.com
Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults
Phase 1
Completed
- Conditions
- Influenza Vaccine
- Interventions
- Biological: Cam2020 M2SR H3N2 influenza vaccineBiological: Fluzone HD IIVOther: IN PlaceboOther: IM Placebo
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- FluGen Inc
- Target Recruit Count
- 303
- Registration Number
- NCT05163847
- Locations
- 🇺🇸
United Medical Research, Port Orange, Florida, United States
🇺🇸Velocity Clinical Research, Cedar Park, Texas, United States
🇺🇸Rochester Clinical Research, Rochester, New York, United States
Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old
Phase 1
Completed
- Conditions
- Influenza Vaccine
- Interventions
- Biological: Sing2016 M2SR H3N2 influenza vaccineOther: Placebo
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- FluGen Inc
- Target Recruit Count
- 122
- Registration Number
- NCT04785794
- Locations
- 🇺🇸
Johnson County Clin Trials, Lenexa, Kansas, United States
🇺🇸Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸Accel Clinical, DeLand, Florida, United States
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
Phase 1
Completed
- Conditions
- Influenza A
- Interventions
- Other: PlaceboBiological: LD Sing2016 M2SR H3N2 influenza vaccineBiological: MD Sing2016 M2SR H3N2 influenza vaccineBiological: HD Sing2016 M2SR H3N2 influenza vaccineBiological: LD Bris10 M2SR H3N2 influenza vaccine
- First Posted Date
- 2019-06-26
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- FluGen Inc
- Target Recruit Count
- 206
- Registration Number
- NCT03999554
- Locations
- 🇺🇸
AMR Lexington, Lexington, Kentucky, United States
🇺🇸AMR Norfolk, Norfolk, Virginia, United States
🇺🇸JCCT, Lenexa, Kansas, United States
Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers
Phase 1
Completed
- Conditions
- Flu
- Interventions
- Other: PlaceboBiological: the H3N2 M2SR monovalent influenza vaccine
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- FluGen Inc
- Target Recruit Count
- 96
- Registration Number
- NCT02822105
- Locations
- 🇺🇸
JCCT, Lenexa, Kansas, United States
Site Selection for Intracutaneous Saline Delivery
Not Applicable
Completed
- Conditions
- Intracutaneous Drug Delivery
- Interventions
- Device: Injection to forearmDevice: Injection to thighDevice: Injection to deltoid
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- FluGen Inc
- Target Recruit Count
- 12
- Registration Number
- NCT01767324
- Locations
- 🇺🇸
Accelovance Inc, Melbourne, Florida, United States
Intracutaneous Delivery of Varied Dose Volumes of Saline
Not Applicable
Completed
- Conditions
- Influenza
- Interventions
- Device: FLUGEN 101.2 device
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- FluGen Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01767337
- Locations
- 🇺🇸
Accelovance Inc, Melbourne, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath